Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study.
hepatitis
immune checkpoint inhibitor
immune‐related adverse event
mycophenolate mofetil
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
04
09
2022
revised:
17
12
2022
accepted:
12
01
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
1
3
2023
Statut:
epublish
Résumé
To investigate the outcomes in eight Japanese patients with cancer treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor treatment-induced severe immune-related hepatitis (ir-hepatitis) and the efficacy and safety of MMF. We retrospectively examined patient background, treatment course, as well as examination and imaging data using electronic medical records. The ratio of male to female patients was 7:1, and the median age was 60 years (27-72 years). There were five and two cases of kidney cancer and malignant melanoma, respectively, and one case of lung cancer. The median number of days until MMF administration in addition to systemic corticosteroid therapy after the onset of ir-hepatitis was 14.5 (2-42). The patients were categorized as four "good responders" who showed an improvement in the liver function tests following MMF treatment and four "poor responders" who did not. Furthermore, the time from the onset of ir-hepatitis to initial MMF administration was significantly shorter in good responders (median 3 days, range 2-15 days) than in poor responders (median 25.5 days, range 14-42 days) ( According to these findings, early recognition of corticosteroid refractoriness and the use of MMF may be beneficial in patients with ir-hepatitis.
Sections du résumé
Background and Aim
UNASSIGNED
To investigate the outcomes in eight Japanese patients with cancer treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor treatment-induced severe immune-related hepatitis (ir-hepatitis) and the efficacy and safety of MMF.
Methods
UNASSIGNED
We retrospectively examined patient background, treatment course, as well as examination and imaging data using electronic medical records.
Results
UNASSIGNED
The ratio of male to female patients was 7:1, and the median age was 60 years (27-72 years). There were five and two cases of kidney cancer and malignant melanoma, respectively, and one case of lung cancer. The median number of days until MMF administration in addition to systemic corticosteroid therapy after the onset of ir-hepatitis was 14.5 (2-42). The patients were categorized as four "good responders" who showed an improvement in the liver function tests following MMF treatment and four "poor responders" who did not. Furthermore, the time from the onset of ir-hepatitis to initial MMF administration was significantly shorter in good responders (median 3 days, range 2-15 days) than in poor responders (median 25.5 days, range 14-42 days) (
Conclusions
UNASSIGNED
According to these findings, early recognition of corticosteroid refractoriness and the use of MMF may be beneficial in patients with ir-hepatitis.
Identifiants
pubmed: 36852148
doi: 10.1002/jgh3.12868
pii: JGH312868
pmc: PMC9958334
doi:
Types de publication
Journal Article
Langues
eng
Pagination
87-97Informations de copyright
© 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33144335
PLoS One. 2016 Jul 29;11(7):e0160221
pubmed: 27472273
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Klin Onkol. 2019 Spring;32(2):133-138
pubmed: 30995854
Am J Surg Pathol. 2015 Aug;39(8):1075-84
pubmed: 26034866
Intern Med. 2020 Dec 1;59(23):3055-3059
pubmed: 32727989
Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178
pubmed: 28173241
Oxf Med Case Reports. 2020 May 23;2020(4):omaa027
pubmed: 32477577
Clin Case Rep. 2020 Dec 04;9(2):654-659
pubmed: 33598220
Hepatology. 2020 Dec;72(6):2235-2238
pubmed: 32484945
Mod Pathol. 2018 Jun;31(6):965-973
pubmed: 29403081
J Dtsch Dermatol Ges. 2017 Sep;15(9):933-935
pubmed: 28872228
Liver Int. 2019 Jun;39(6):1002-1013
pubmed: 30716203
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):212-216
pubmed: 29227329
Dig Dis Sci. 2012 Aug;57(8):2233-40
pubmed: 22434096
J Clin Oncol. 2011 Mar 20;29(9):e237-40
pubmed: 21220617
Case Rep Oncol. 2020 Apr 30;13(1):478-484
pubmed: 32508620
Hepatol Int. 2019 May;13(3):248-252
pubmed: 30607787
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Hepatology. 2002 Jan;35(1):7-13
pubmed: 11786954
JGH Open. 2022 Apr 22;6(5):309-316
pubmed: 35601125
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
J Gastroenterol Hepatol. 2020 Oct;35(10):1782-1788
pubmed: 32187734